ArticleNature communications2018
3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in Engineering Human Tissue Models.Frontiers in bioengineering and biotechnology · 2020Pooled it
- In Vitro Three-Dimensional Human Liver Model for Drug-Induced Liver and Bile Duct Injury Prediction.Toxics · 2026Article
- Merkel cell polyomavirus exploits extracellular vesicles for skin infection and host immune evasion through activated Wnt signaling.PLoS pathogens · 2026Article
- Microengineering the Liver: Strategies for Constructing Functional Liver-on-a-Chip Devices.Exploration (Beijing, China) · 2026Review
- Review
- Toward continuous monitoring systems: emerging trends of on-chip sensors in organ-on-a-chip.Microsystems & nanoengineering · 2026Review
- Human organoids and organ-on-chip systems for AI-guided therapeutic discovery against emerging and re-emerging infections.Frontiers in pharmacology · 2026Review
- Revolutionizing toxicological risk assessment: integrative advances in new approach methodologies (NAMs) and precision toxicology.Archives of toxicology · 2025Review
- Constructing biomimetic microenvironments for liver regeneration.Journal of nanobiotechnology · 2025Review
- Advanced 3D In Vitro Liver Fibrosis Models: Spheroids, Organoids, and Liver-on-Chips.Biomimetics (Basel, Switzerland) · 2025Review
- Real-Time, Continuous Monitoring of Tissue Chips as an Emerging Opportunity for Biosensing.Sensors (Basel, Switzerland) · 2025Review
- Liver-Skin Microphysiological System for Evaluating Topical Drug Delivery-Induced Liver Injury.ACS omega · 2025Article
- Targeting Metastasis: Exploring the Impact of Microbial Infections on Cancer Progression Through Innovative Biological Models.Current microbiology · 2025Review
- In vitro liver models for toxicological research.Drug metabolism and pharmacokinetics · 2025Review
- Organs on chips: fundamentals, bioengineering and applications.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- The Interface of Gene Editing with Regenerative Medicine.Engineering (Beijing, China) · 2025Article
- Liver organoids: Current advances and future applications for hepatology.Clinical and molecular hepatology · 2025Review
- Integration of nanobiosensors into organ-on-chip systems for monitoring viral infections.Nano convergence · 2024Review
- Microphysiological systems to advance human pathophysiology and translational medicine.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Review
- Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
With more than 240 million people infected, hepatitis B virus (HBV) is a major health concern. The inability to mimic the complexity of the liver using cell lines and regular primary human hepatocyte (PHH) cultures pose significant limitations for studying host/pathogen interactions. Here, we describe a 3D microfluidic PHH system permissive to HBV infection, which can be maintained for at least 40 days. This system enables the recapitulation of all steps of the HBV life cycle, including the replication of patient-derived HBV and the maintenance of HBV cccDNA. We show that innate immune and cytokine responses following infection with HBV mimic those observed in HBV-infected patients, thus allowing the dissection of pathways important for immune evasion and validation of biomarkers. Additionally, we demonstrate that the co-culture of PHH with other non-parenchymal cells enables the identification of the cellular origin of immune effectors, thus providing a valuable preclinical platform for HBV research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.